Related references
Note: Only part of the references are listed.An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
Alessandra Mangia et al.
GASTROENTEROLOGY (2010)
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
Alexander J. Thompson et al.
GASTROENTEROLOGY (2010)
Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin
Jeanette J. McCarthy et al.
GASTROENTEROLOGY (2010)
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch et al.
GASTROENTEROLOGY (2010)
Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes
Marco Antonio Montes-Cano et al.
HEPATOLOGY (2010)
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients
Hiromi Abe et al.
JOURNAL OF HEPATOLOGY (2010)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas et al.
NATURE (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah et al.
NATURE GENETICS (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Olav Dalgard et al.
HEPATOLOGY (2008)
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
Sanaa M. Kamal et al.
HEPATOLOGY (2007)
Multiple displacement amplification to create a long-lasting source of DNA for genetic studies
L Lovmar et al.
HUMAN MUTATION (2006)
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
JJ Feld et al.
NATURE (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
O Dalgard et al.
HEPATOLOGY (2004)
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
CT Wai et al.
HEPATOLOGY (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Share Paper
